[A20-45] Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2020
Commission awarded on 12.05.2020 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Adults with opioid-induced constipation who have previously been treated with a laxative
Added benefit not proven for either of both research questions (further laxative not subject to medical prescription or prescribable medical device still [RQ1] or no longer [RQ2] an option).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-55||Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G20-23||Naldemedine (opioid-induced constipation) - Addendum to Commission A20-45||Commission completed|